PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 7, 2024New England Journal of Medicine1,920 citationsOpen Access

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

SHStephen A. HarrisonUniversity of OxfordPBPierre BédossaUniversité Paris-SudCGCynthia D. GuyDuke University Health System

Key Points

Key points are not available for this paper at this time.

Abstract

Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Harrison et al. (2024) studied this question.

synapsesocial.com/papers/69d7262c424c1fc5df563bebhttps://doi.org/10.1056/nejmoa2309000
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy2010 · 41 citations
  2. 2Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist2013 · 165 citations
  3. 3Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease2010 · 1,918 citations
  4. 4Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation2006 · 6,629 citations
  5. 5Design and validation of a histological scoring system for nonalcoholic fatty liver disease†2005 · 10,833 citations